Texas Permanent School Fund Corp Sells 45,126 Shares of Dynavax Technologies Corporation $DVAX

Texas Permanent School Fund Corp lessened its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 54.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,228 shares of the biopharmaceutical company’s stock after selling 45,126 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Dynavax Technologies were worth $369,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Osaic Holdings Inc. boosted its position in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,226 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Dynavax Technologies by 1.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock valued at $1,126,000 after purchasing an additional 1,625 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in Dynavax Technologies by 17.9% during the second quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,752 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Dynavax Technologies by 0.4% in the 2nd quarter. Nordea Investment Management AB now owns 782,248 shares of the biopharmaceutical company’s stock worth $7,830,000 after buying an additional 3,171 shares in the last quarter. Finally, Teza Capital Management LLC grew its stake in shares of Dynavax Technologies by 22.8% in the 1st quarter. Teza Capital Management LLC now owns 26,592 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 4,942 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DVAX shares. Wall Street Zen upgraded shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX opened at $15.38 on Friday. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. Dynavax Technologies Corporation has a 12 month low of $9.20 and a 12 month high of $15.49. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.57 and a beta of 0.89. The firm’s 50-day moving average is $11.10 and its 200 day moving average is $10.58.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. Research analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.